BrightPath Biotherapeutics Co., Ltd. reported consolidated earnings results for the six months ended September 30, 2018. For the period, the company reported net sales of JPY 142.435 million compared to JPY 182.683 million a year ago. Operating loss was JPY 826.092 million compared to JPY 685.920 million a year ago. Loss before income tax was JPY 1,015.067 million compared to JPY 685.187 million a year ago. Net loss was JPY 1,017.343 million or JPY 24.31 per share compared to JPY 688.607 million or JPY 18.45 per share a year ago.

For the year ending March 31, 2019, on consolidated basis, the company expects net sales of JPY 150 million, operating loss of JPY 2,200 million and loss attributable to owners of parents of JPY 2,200 million or 52.59 per share.